NPCE - צמיחת הכנסות ב-12 חודשים נגררים NeuroPace Medical

NeuroPace, Inc. manufactures unique epilepsy treatment systems in the US, ensuring steady growth of its customer base. The trailing twelve-month sales growth rate helps filter out market noise and determine the actual speed of business expansion, where -0.30 describes the current status of the metric. The company's revenues are based on the sale and service of RNS implants. Independence from macroeconomic factors makes the asset a reliable defensive tool.
neuropace.com (NPCE) - פילוחי מדדים ודוחות פיננסיים

Investors are assessing the potential of NeuroPace, Inc. (NPCE) through the commercialization rates of its seizure-preventing neurostimulators. This indicator calculates the percentage change in total revenue over the trailing twelve months (LTM) relative to the same period last year, which neutralizes seasonality and reveals the true acceleration of demand. Analysis of the LTM gross revenue dynamics confirms the resilience of the innovative product's market expansion and determines the asset's investment attractiveness.